NeRRe Therapeutics Spun Out Of GSK’s Unwanted Neuroscience Assets
This article was originally published in The Pink Sheet Daily
Executive Summary
The third biotech company to be spun out of GlaxoSmithKline’s unwanted neurosciences R&D is NeRRe Therapeutics, which has a neurokinin antagonist ready for Phase II clinical studies in an undisclosed indication.